Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - BRAF V600E
 More »

  • GSK Hits Trifecta with Melanoma Drug, Dx Approvals
    Both drugs are oral therapies approved for one indication, metastatic or unresectable melanoma in adult patients with the BRAF V600E mutation, which accounts for about 85% of all ...
    5-30-2013
  • Companion Diagnostics: 52 Pick-Up
    ... COBAS 4800 BRAF V600 Mutation Test Sponsor/Developer: Roche Molecular Systems Intended Use/Indications for Use: Intended for the qualitative detection of the BRAF V600E mutation in ...
    5-9-2013
  • Development and Evolution of PCR
    ... In some cases, the assay is co-developed with the drug and is known as a companion diagnostic (e.g., Zelboraf, which targets melanoma tumors harboring the BRAF V600E mutation). The ...
    4-1-2013
  • Advertorial: Swift Biosciences
    ... However, the technology is readily applicable to other mutations and infectious disease testing. In 2012, Swift launched two Research Use Only (RUO) myT Primer sets for BRAF V600E/...
    4-1-2013
  • Tumor Bank Lends Expertise to Drug Firms
    ... The FDA has approved drugs that target BRAF mutations, such as Roche's recently released Zelforaf(tm) (vemurafenib) for treating melanoma patients with the BRAF V600E mutation. ...
    2-1-2013
  • Improving Molecular Genetic Testing
    Key mutations are shown for EGFR, KRAS, PI3K, and BRAF. Other genes (not shown) are also ... For B-Raf V600E, three cell lines were created on different parental backgrounds each with ...
    12-1-2012
  • BRAF Mutation Detection
    BRAF mutations. myT BRAF-Ultra can detect less than 10 copies of mutant BRAF V600E/K with low breakthrough amplification from a background of 10,000 wild-type genomic DNA copies. ...
    11-1-2012
  • Bold Predictions for Future Cancer Tests
    growth driven by incorporation of companion diagnostics (KRAS, EGFR, BRAF V600E) into clinical guidelines and then rapid development of clinical next-generation sequencing (NGS). ...
    9-1-2012
  • Quest Diagnostics Launches Molecular Tests for Thyroid Cancer
    The markers are BRAF V600E, RAS, RET/PTC, and PAX8/PPAR gamma, which are associated with papillary and follicular thyroid cancer. "The removal of a healthy thyroid gland is an ...
    6-1-2012
  • Ventana Licenses BRAF V600E Mutation Antibody for Diagnostic...
    ...rebsforschungszentrum, DKFZ) and University Hospital Heidelberg to commercialize an immunohistochemistry (IHC) primary antibody to detect the V600E BRAF mutation protein in cancer. ...
    5-31-2012
  • This Time Last Year: Diagnostic Deals, mAb Therapeutics, and...
    ... FDA approved Yervoy in March 2011 for unresectable or metastatic melanoma and Zelboraf last August for late-stage or unresectable BRAF V600E melanoma. The combo will be tested in ...
    5-30-2012
  • Digital PCR: Improving Nucleic Acid Quantification
    ... For the HapMap MRGPRX1 sample, copy number states from 1 up to 6 were completely resolved ( Figure 1 ). Rare Event Detection Figure 2. Droplet digital PCR detection of BRAF V600E ...
    5-1-2012
  • FDA Clears Roche's Erivedge for Treating Advanced Basal Cell...
    In August 2011 FDA approved another Roche skin cancer drug, Zelboraf (tm) (vemurafenib), for the treatment of BRAF V600E mutation-positive, inoperable, or metastatic melanoma. The ...
    1-31-2012
  • Scientists Say EGFR Inhibitors Are the Answer to Vemurafenib...
    vemurafenib (PLX4032) is an effective therapy for melanomas carrying the BRAF V600E mutation but is much less effective against colon cancers carrying exactly the same mutation. ...
    1-27-2012
  • FDA New Drug Approvals in 2011 Outpace Recent Past
    Zelboraf, an oral kinase inhibitor, acts by blocking the function of the V600E-mutated BRAF protein. The mutation is present in about half the patients with late-stage melanomas. ...
    1-6-2012
  • More »

    Journal Articles

  • Upregulation of Endocrine Gland-Derived Vascular Endothelial...
    Daniela Pasquali, Angela Santoro, Pantaleo Bufo, Giovanni Conzo, William J Deery, Andrea Renzullo, Giacomo Accardo, Valentina Sacco, Antonio Bellastella, Giuseppe Pannone
    Thyroid
    The oncogene BRAF V600E mutation is associated with poor clinical outcome of papillary thyroid cancer (PTC) and can independently predict its recurrence. Design: Our hypothesis was ...
  • Aberrant Promoter Methylation in Overexpression of CITED1 in...
    Miho Sassa, Yoshitaka Hayashi, Reiko Watanabe, Toyone Kikumori, Tsuneo Imai, Junichi Kurebayashi, Tetsuya Kiuchi, Yoshiharu Murata
    Thyroid
    In PTC specimens without a BRAF mutation, two CpGs were more heavily methylated than in PTC specimens with the BRAF V600E mutation. Pharmacological inhibition of methylation in ...
  • Suspicious Ultrasound Characteristics Predict BRAF V600E-Positive...
    Adam S. Kabaker, Mitchell E Tublin, Yuri E. Nikiforov, Michaele J. Armstrong, Steven P. Hodak, Michael T. Stang, Kelly L. McCoy, Sally E. Carty, Linwah Yip
    Thyroid
    Suspicious Ultrasound Characteristics Predict BRAF V600E-Positive Papillary Thyroid Carcinoma Thyroid
  • Molecular Diagnosis of a BRAF Papillary Thyroid Carcinoma with...
    John A. Copland, Laura A. Marlow, Sandra F. Williams, Stefan K. Grebe, Michelle L. Gumz, William J. Maples, Victor E. Silverman, Robert C. Smallridge
    Thyroid
    The BRAF V600E mutation was detected. The karyotype was 44-48,XY, + der(1) t(1;9)(p13;p13),add(9)(p13),-17,-18, + 0-3mar[cp20]. Lovastatin, gefitinib, paclitaxel, depsipeptide, and ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Top Paid Women in Biopharma

Do you think the women on our list of the 20 top paid women executives in biopharma are underpaid?

Suggest a Poll